Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study aimed to investigate the efficacy and safety of iguratimod (T-614) in combination with methotrexate (MTX) for active rheumatoid arthritis (RA) patients. Sixty active RA patients were enrolled according to the 2010 American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification criteria, and were randomized into MTX + T-614 group and MTX group. T-614 was orally administered at a dosage of 50 mg/day (25 mg twice daily) for 24 weeks. MTX was orally administered to RA patients at a stable weekly dosage of 10 mg/week for the first 4 weeks and subsequent 12.5 mg/week for the later 20 weeks. Clinical features at baseline and efficacy endpoints of the ACR 20 % response (ACR20), ACR50, ACR70, and adverse events at 24 weeks were evaluated, respectively. After 24 weeks of treatment, clinical features at baseline, including counts for tender joints and swelling joints, visual analog scale for pain, patient’s and physician’s global assessment, erythrocyte sedimentation rate, C-reactive protein, disease activity score 28, health assessment questionnaire, simplified disease activity index, and ACR50 in the MTX + T-614 group, showed statistically significant differences comparing with the MTX group (P < 0.05). There was no significant increase in adverse events in the MTX + T-614 group comparing with the MTX group (P > 0.05). The combination of MTX and T-614 therapy appeared to have a good efficacy and safety for active RA and was superior to MTX-alone therapy after 24 weeks of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chao C-C, Chen S-J, Adamopoulos IE, Davis N, Hong K, Vu A, Kwan S, Fayadat-Dilman L, Asio A, Bowman EP (2011) Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 44(3):243–252

    Article  CAS  PubMed  Google Scholar 

  2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581

    Article  PubMed  Google Scholar 

  3. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219

    Article  CAS  PubMed  Google Scholar 

  4. Barnabe C, Martin BJ, Ghali WA (2011) Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 63(4):522–529

    Article  CAS  Google Scholar 

  5. Gaffo A, Saag KG, Curtis JR (2006) Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63(24):2451–2465

    Article  CAS  PubMed  Google Scholar 

  6. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(4):583–589

    Article  PubMed Central  PubMed  Google Scholar 

  7. Saunders S, Capell H, Stirling A, Vallance R, Kincaid W, McMahon A, Porter D (2008) Triple therapy in early active rheumatoid arthritis: a randomized, single‐blind, controlled trial comparing step‐up and parallel treatment strategies. Arthritis Rheum 58(5):1310–1317

    Article  CAS  PubMed  Google Scholar 

  8. Van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P, Settas L, Bijlsma J, Todesco S, Dougados M (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63(5):508–516

    Article  PubMed Central  PubMed  Google Scholar 

  9. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta‐analysis of randomized controlled trials. Arthritis Rheum 66(4):803–812

    Article  CAS  Google Scholar 

  10. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370(9602):1861–1874

    Article  CAS  PubMed  Google Scholar 

  11. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7(1):e30275

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Zhang J, McVie T, Howard G (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 64(9):2824–2835

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443

    Article  CAS  PubMed  Google Scholar 

  14. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Rv V, Sharp J, Perez JL, Spencer‐Green GT (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26–37

    Article  CAS  PubMed  Google Scholar 

  15. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M (2007) Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17(1):1–9

    Article  PubMed  Google Scholar 

  16. Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K (2013) OP0205 efficacy and safety evaluation of iguratimod, a novel anti-rheumatic agent—a double-blind, comparative study of iguratimod-MTX combination in rheumatoid arthritis patients with an inadequate response to MTX. Ann Rheum Dis 71(3):124–125

    Google Scholar 

  17. Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K (2014) Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 24(3):410–418

    Article  CAS  PubMed  Google Scholar 

  18. Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M (2013) Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23(3):430–439

    Article  CAS  PubMed  Google Scholar 

  19. Lu L, Bao C, Dai M, Jl T, Fan W, Du F, Yang N, Zhao Y, Chen Zw XJ (2009) Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Care Res 61(7):979–987

    Article  CAS  Google Scholar 

  20. Wei Y, Sun X, Hua M, Tan W, Wang F, Zhang M (2014) Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed Res Int

  21. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45

    Article  CAS  PubMed  Google Scholar 

  22. Yan Q, Du F, Huang X, Fu Q, Chen S, Dai D, Bao C (2014) Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice. PLoS One 9(10):e108273

    Article  PubMed Central  PubMed  Google Scholar 

  23. Luo Q, Sun Y, Jin B, Zheng W, Shao F (2014) Iguratimod synergizes with methotrexate to exert anti-inflammatory and bone-protective effect and block the progression of collagen-induced arthritis in mice. Biochem Pharmacol 3(135):2167–0501.1000135

    Google Scholar 

  24. Lu L-j, J-l T, Bao C-d, X-h H, Xu SL-y, J-h LX-f, Wu H-x (2008) Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J 121(7):615

    CAS  PubMed  Google Scholar 

  25. Yoshizaki K, Nakazawa S, Nishikawa T, Isobe T (2012) P080 pathogenic role of IL-6 on the inducation of acute phase proteins, CRP and SAA in rheumatoid arthritis a chronic inflammatory disease. Cytokine 59(3):544–545

    Article  Google Scholar 

  26. Okuda O, Yoshida N, Maini RN (2014) Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate. Google Patents

  27. Kremer JM, Blanco R, Brzosko M, Burgos‐Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63(3):609–621

    Article  CAS  PubMed  Google Scholar 

  28. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M (2007) Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol 17(1):10–16

    Article  PubMed  Google Scholar 

  29. Garcia AJ, Tom C, Guemes M, Polanco G, Mayorga ME, Wend K, Miranda‐Carboni GA, Krum SA (2013) ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis. J Bone Miner Res 28(2):283–290

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Mucke H (2012) Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc) 48(9):577–586

    CAS  Google Scholar 

  31. Du F, Lu L-j FQ, Dai M, J-l T, Fan W, S-l C, Ye P, Shen N, X-f H (2008) T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther 10(6):R136

    Article  PubMed Central  PubMed  Google Scholar 

  32. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O’dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 64(5):640–647

    Article  Google Scholar 

  33. Bluett J, Ibrahim I, Plant D, Hyrich K, Morgan A, Wilson A, Isaacs J, Gaston H, Mulherin D, Price T (2014) Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Pharmacogenomics J 14(2):171–175

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Kushner I (1991) C-reactive protein in rheumatology. Arthritis Rheum 34(8):1065–1068

    Article  CAS  PubMed  Google Scholar 

  35. Brigden ML (1999) Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician 60(5):1443–1450

    CAS  PubMed  Google Scholar 

  36. Nielung L, Christensen R, Danneskiold-Samsøe B, Bliddal H, Holm CC, Ellegaard K, Slott Jensen H, Bartels EM (2015) Validity and agreement between the 28-joint disease activity score based on C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Arthritis Rheum 2015

  37. Tamhane A, Redden DT, McGwin G, Brown EE, Westfall AO, Reynolds RJ, Hughes LB, Conn DL, Callahan LF, Jonas BL (2013) Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis. J Rheumatol 40(11):1812–1822

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a scientific grant from the Department of Education in Jiangxi Province (GJJ13151).

Disclosures

None.

Author information

Authors and Affiliations

  1. Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, No. 1 MinDe Road, Nanchang, 330006, China

    Xin-Wang Duan, Xiu-Ling Zhang, Shao-Yuan Mao, Jing-Jing Shang & Xiao-Dong Shi

Authors
  1. Xin-Wang Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiu-Ling Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shao-Yuan Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing-Jing Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Dong Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xin-Wang Duan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duan, XW., Zhang, XL., Mao, SY. et al. Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol 34, 1513–1519 (2015). https://doi.org/10.1007/s10067-015-2999-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-2999-6

Keywords

Search

Navigation